Molecular Endocrinology, doi:10.1210/me.2004-0279
Molecular Endocrinology 19 (4): 1012-1023
Copyright © 2005 by The Endocrine Society
Relaxin Stimulates Protein Kinase C
Translocation: Requirement for Cyclic Adenosine 3',5'-Monophosphate Production
Bao T. Nguyen and
Carmen W. Dessauer
Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, Texas 77030
Address all correspondence and requests for reprints to: Carmen W. Dessauer, Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, Texas 77030. E-mail: Carmen.W.Dessauer{at}uth.tmc.edu.
Relaxin is a polypeptide hormone that activates the leucine-rich repeat containing G protein-coupled receptors, LGR7 and LGR8. In an earlier study, we reported that relaxin produces a biphasic time course and the second wave of cAMP is highly sensitive to phosphoinositide-3 kinase inhibitors (LY294002 and wortmannin). LY294002 inhibits relaxin-mediated increases in cAMP production by 4050% across a large range of relaxin concentrations. Here we show that protein kinase C
(PKC
) is a component of relaxin signaling in THP-1 cells. Sphingomyelinase increases cAMP production due to the release of ceramide, a direct activator of PKC
. Chelerythrine chloride (a general PKC inhibitor) inhibits relaxin induced cAMP production to the same degree (
40%) as LY294002. Relaxin stimulates PKC
translocation to the plasma membrane in THP-1, MCF-7, pregnant human myometrial 131, and mouse mesangial cells, as shown by immunocytochemistry. PKC
translocation is phosphoinositide-3 kinase dependent and independent of cAMP production. Antisense PKC
oligodeoxynucleotides (PKC
-ODNs) deplete both PKC
transcript and protein levels in THP-1 cells. PKC
-ODNs abolish relaxin-mediated PKC
translocation and inhibit relaxin stimulation of cAMP by 40%, as compared with mock and random ODN controls. Treatment with LY294002 in the presence of PKC
-ODNs results in little further inhibition. In summary, we present a novel role for PKC
in relaxin-mediated stimulation of cAMP.
This article has been cited by other articles:

|
 |

|
 |
 
M. L. Halls, R. A. D. Bathgate, and R. J. Summers
Comparison of Signaling Pathways Activated by the Relaxin Family Peptide Receptors, RXFP1 and RXFP2, Using Reporter Genes
J. Pharmacol. Exp. Ther.,
January 1, 2007;
320(1):
281 - 290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Halls, R. A. D. Bathgate, and R. J. Summers
Relaxin Family Peptide Receptors RXFP1 and RXFP2 Modulate cAMP Signaling by Distinct Mechanisms
Mol. Pharmacol.,
July 1, 2006;
70(1):
214 - 226.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Goichberg, A. Kalinkovich, N. Borodovsky, M. Tesio, I. Petit, A. Nagler, I. Hardan, and T. Lapidot
cAMP-induced PKC{zeta} activation increases functional CXCR4 expression on human CD34+ hematopoietic progenitors
Blood,
February 1, 2006;
107(3):
870 - 879.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Samuel
Relaxin: Antifibrotic Properties and Effects in Models of Disease
Clin. Med. Res.,
November 1, 2005;
3(4):
241 - 249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. IVELL, R. ANAND-IVELL, and O. BARTSCH
Relaxin Signaling from Natural Receptors
Ann. N.Y. Acad. Sci.,
May 1, 2005;
1041(1):
280 - 287.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by The Endocrine Society